← All trials
NCT02256618
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2014
- Primary completion
- Oct 31, 2017
- Completion date
- Jul 31, 2019
- First posted
- Oct 3, 2014
- Last posted
- Oct 29, 2019
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Neonatal Encephalopathy Consortium, JapanLead sponsor
- Nagoya UniversityCollaborator
- National Cerebral and Cardiovascular CenterCollaborator
- Osaka City UniversityCollaborator
- Osaka City UniversityStudy director
- Yodogawa Christian HospitalCollaborator
- Kurashiki Central HospitalCollaborator
- National Center for Child Health and Development, JapanCollaborator
- Tokyo Women's Medical UniversityCollaborator
- Osaka City UniversityOfficial
- Saitama Medical UniversityCollaborator
- Osaka City General HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.